糖尿病神经病变市场规模、份额、成长分析、按疾病类型、按药物类别、按分销管道、按地区 - 行业预测，2024-2031 年

2022年，糖尿病神经病变的全球市场规模为36亿美元，从2023年的38.5亿美元成长到2031年的65.6亿美元，预测期（2024-2031）预计复合年增长率为6.9%。

糖尿病神经病变是一种损害与高血糖相关的神经的疾病，也是长期糖尿病患者面临的重大挑战。目前尚无治疗方法，因此有效的管理和预防策略至关重要。这种复杂性强调了监管机构核准新治疗剂和治疗方法的必要性。鑑于糖尿病患者糖尿病神经病变的高盛行率，该领域的公司存在巨大的市场机会。随着认识和诊断的提高，对满足糖尿病患者需求的创新解决方案的需求预计将激增，为医疗保健市场的成长和发展提供良好的前景。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究

糖尿病神经病变市场规模：依疾病类型

• 市场概况
• 週边神经神经病变
• 自主神经病变
• 近端神经病变
• 局部神经病变

糖尿病神经病变市场规模：依药物类别

• 市场概况
• 辣椒素
• 阿片类药物
  • 氢可酮
  • 其他的
• 非类固醇消炎剂(NSAID)
  • Ibuprofen
  • 萘普生
• 抗忧郁症
  • 三环抗忧郁药物（Tcas）
  • 阿米替林
  • 丙咪嗪
  • 血清素和去甲肾上腺素再回收抑制剂(SNRIS)
  • Duloxetine
  • 选择性血清素再回收抑制剂（SSRI）
  • 西酞普兰
  • 帕罗西汀
  • 抗惊厥药
  • Gabapentin
  • Pregabalin
  • 托吡酯
• 其他的

糖尿病神经病变市场规模：按分销管道

• 市场概况
• 医院药房
• 零售药房

糖尿病神经病变市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Abbott Laboratories
• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Pharmaceuticals, Inc.
• Astellas Pharma US, Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• NeuroMetrix Inc.
• Helixmith Co., Ltd.
• Johnson & Johnson Services, Inc.
• Daiichi Sankyo Company, Limited
• Ionis Pharmaceuticals, Inc.
• Akcea Therapeutics, Inc.
• Alfasigma USA, Inc.
• ExeGi Pharma LLC

结论和建议

Global Diabetic Neuropathy Market size was valued at USD 3.6 billion in 2022 and is poised to grow from USD 3.85 billion in 2023 to USD 6.56 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2024-2031).

Diabetic neuropathy, a nerve-damaging condition linked to hyperglycemia, poses significant challenges for long-term diabetes sufferers, where symptoms often go unnoticed until considerable nerve damage occurs. As there is currently no cure, effective management and preventive strategies are crucial. This complexity emphasizes the need for regulatory agencies to approve new treatment products and therapeutic approaches. With the high prevalence of diabetic neuropathy among individuals with diabetes, there exists a substantial market opportunity for companies operating in this sector. As awareness and diagnosis improve, businesses can expect a surge in demand for innovative solutions tailored to address the needs of those affected by this condition, presenting lucrative prospects for growth and development in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Neuropathy Market Segmental Analysis

Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is primarily driven by the increasing prevalence of diabetes worldwide, leading to a higher demand for diabetic neuropathy treatment. As diabetes rates continue to rise, the market is expected to experience steady growth throughout the forecast period. Contributing factors include the rise in obesity, coronary heart disease, and various complications associated with diabetes, such as neuropathy. Additionally, urbanization plays a significant role in this trend, fostering sedentary lifestyles characterized by increased carbohydrate intake and reduced physical activity, which further exacerbates the incidence of diabetes and, consequently, the need for effective management of diabetic neuropathy.

Restraints in the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market faces several restraints that impede its growth potential. One significant challenge is the high cost of medications specifically designed for treating this condition, which may deter patients from pursuing pharmaceutical options. Additionally, the increasing popularity of alternative treatments, such as radiotherapy and physiotherapy, presents competition as these methods are often perceived as more comfortable and capable of delivering satisfactory results. Furthermore, stringent regulations, instances of product recalls, and delays in obtaining clearances from regulatory bodies like the Food and Drug Administration also contribute to the difficulties faced by the market in expanding its reach and efficacy.

Market Trends of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is witnessing a dynamic trend characterized by innovations in high-tech therapeutic solutions aimed at enhancing treatment efficacy. During the forecast period, companies are focusing on developing advanced products, including transdermal patches, mouthwashes, and powders, to address the complexities of diabetic neuropathy. The introduction of sophisticated medication delivery systems, such as needle-free injection devices, is emerging as a key strategy to mitigate challenges associated with traditional pharmaceutical methods. This surge in demand for novel drug delivery forms-spanning oral, transdermal, parenteral, and inhalation routes-is propelling market growth, reflecting an increasing consumer and healthcare provider interest in effective management of the condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2024-2031)

• Market Overview
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2024-2031)

• Market Overview
• Capsaicin
• Opioid
  • Morphine
  • Others
• Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • Ibuprofen
  • Naproxen
• Antidepressants
  • Tricyclic Antidepressants (Tcas)
  • Amitriptyline
  • Imipramine
  • Serotonin and Norepinephrine Reuptake Inhibitors (Snris)
  • Duloxetine
  • Selective Serotonin Reuptake Inhibitors (Ssris)
  • Citalopram
  • Paroxetine
  • Anticonvulsant Drugs
  • Gabapentin
  • Pregabalin
  • Topiramate
• Other

Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies

Global Diabetic Neuropathy Market Size & CAGR (2024-2031)

• North America (Disorder Type, Drug Class, Distribution Channel)
  • USA
  • Canada
• Europe (Disorder Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma US, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroMetrix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helixmith Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alfasigma USA, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ExeGi Pharma LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations